In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo signs $8.6bn Elan takeover deal

This article was originally published in Scrip

Executive Summary

Perrigo has agreed a cash and shares takeover of Elan which values the Irish firm at $16.50 per share. The total value of the deal is $8.6bn at Perrigo's share price of $134.23 at close of business on 26 July.

You may also be interested in...



Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine

BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Buyers And Sellers: How Corporate Transactions Are Shaping Pharma

Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.

Topics

Related Companies

UsernamePublicRestriction

Register

SC022250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel